Logo do repositório
 
Publicação

Connective tissue disease-associated interstitial lung disease

2022-03Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorOliveira, R. P.
dc.contributor.authorRibeiro, R.
dc.contributor.authorMelo, L.
dc.contributor.authorGrima, B.
dc.contributor.authorOliveira, S.
dc.contributor.authorAlves, J. D.
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutionCentro de Estudos de Doenças Crónicas (CEDOC)
dc.contributor.pblElsevier Espana S.L.U
dc.date.accessioned2020-03-16T23:31:17Z
dc.date.available2020-03-16T23:31:17Z
dc.date.issued2022-03
dc.description.abstractBackground: Connective tissue diseases (CTD) are frequently associated with interstitial lung disease (ILD), significantly impacting their morbidity and mortality. Aim: Analyze the experience of an autoimmune specialized unit on treating CTD-ILD and characterize the population based on most frequent diseases, imaging patterns, lung function tests results, serology and treatment. Assess mortality and mortality predictors in these patients. Methods: Retrospective, descriptive and statistical analysis of the CTD-ILD patients followed up at an autoimmune diseases unit during a 6-year period. Results: Over the study period, 75 patients with CTD-ILD were treated with a mean follow-up of 49 ± 31 months. The most frequent CTD were systemic sclerosis and rheumatoid arthritis. ILD was diagnosed prior to CTD in 8% of patients and concomitantly in 35%. Nonspecific interstitial pneumonia was the CT pattern in 60% and 35% had an isolated diminished DLCO on lung function tests. Pulmonary hypertension was present in 12% and it was the single most important mortality predictor (OR 14.41, p = 0.006). Corticosteroids are the mainstay of treatment but biologics were prescribed in 39% of the patients (mostly tocilizumab and rituximab). Two scleroderma patients were recently treated with nintedanib. Conclusions: ILD is a potential complication of every CTD and can impose a dramatic burden on these patients. The clinical relevance of ILD together with their early expression in the course of the disease underlines the importance of the presence of chest physicians in these units.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent290441
dc.identifier.doi10.1016/j.pulmoe.2020.01.004
dc.identifier.issn2531-0429
dc.identifier.otherPURE: 17329803
dc.identifier.otherPURE UUID: 1ff3b746-bb5c-476b-9921-2bff010f653c
dc.identifier.otherScopus: 85079113461
dc.identifier.otherPubMed: 32044296
dc.identifier.otherWOS: 000763636600005
dc.identifier.urihttp://hdl.handle.net/10362/94391
dc.identifier.urlhttps://www.scopus.com/pages/publications/85079113461
dc.language.isoeng
dc.peerreviewedyes
dc.subjectConnective tissue disease
dc.subjectInterstitial lung disease
dc.subjectNintedanib
dc.subjectRheumatoid arthritis
dc.subjectSystemic sclerosis
dc.subjectTocilizumab
dc.subjectPulmonary and Respiratory Medicine
dc.titleConnective tissue disease-associated interstitial lung diseaseen
dc.typejournal article
degois.publication.firstPage113
degois.publication.issue2
degois.publication.lastPage118
degois.publication.titlePulmonology
degois.publication.volume28
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1_s2.0_S2531043720300040_main.pdf
Tamanho:
283.63 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica